



## FERMENTA BIOTECH LIMITED

Investor Presentation | July 2024



Only manufacturer of  
Vitamin D3 in India



Amongst top 3 manufacturers  
of Vitamin D3 globally



Global Presence in  
60+ countries



Proprietary technology to  
manufacture Vitamin D3



55+ Years of Vitamin D3  
manufacturing experience



Both manufacturing facilities certified  
by global regulatory bodies



DSIR approved  
R&D facility



Patents



Big 4 statutory auditor



350+ clients across  
the globe



Backward integrated



Forward Integrating and  
diversifying to offer more  
nutraceutical products

# Company Overview




- Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries.
- With a rich history of seven decades FBL has evolved as a key global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
- FBL manufactures a range of Vitamin D3 variants having an optimal mix between human and animal feed products which have applications across multiple sectors like:


- |                                        |                 |
|----------------------------------------|-----------------|
| 1. Pharmaceuticals                     | 4. Animal feed  |
| 2. Dietary and nutritional supplements | 5. Veterinary   |
| 3. Food and beverage fortification     | 6. Rodenticides |

- The company is also involved in manufacturing of APIs for muscle relaxant and anti-flatulent applications.
- FBL delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment and management.

**Consolidated Revenue (INR Mn) & EBITDA Margins (%)**



**Revenue Mix % (FY24)**





**Mr. Pradeep M. Chandan,**  
**Chairman, Non-Executive Independent Director**

He has been appointed as an Independent Director w.e.f. February 12, 2024, and as the Chairman with effect from April 1, 2024. He is a professional with almost 35 years of experience in the corporate sector, he possesses domain expertise in legal, company secretarial, compliance, corporate governance, ESG reporting, corporate restructuring, intellectual property rights, investor relations, real estate, joint ventures and spearheading greenfield projects etc. Besides being a Fellow member of ICSI, he also holds Bachelor's degrees in both commerce (B.Com) and Law (LLB).



**Ms. Rajeshwari Datla, Non-Executive Director**

She has around five decades of rich experience in management and operations in the pharmaceutical industry. She holds a Bachelor of Science degree. Since joining the Company's Audit Committee in 2005, she has made invaluable contributions to the strategic and decision-making processes, playing an instrumental role in the Company's operations. Ms. Datla also serves as a Director for Dupen Laboratories Private Limited and Lacto-Cosmetics (Vapi) Private Limited.



**Mr Pramod Kasat, Non – Executive Independent Director**

Managing Director of Intellectap Advisory Services. Prior to this, he was associated as Country Head of Investment Banking at IndusInd Bank, Mumbai and has served as Director and Head of Investment Banking at Pioneer Investcorp Ltd. (PINC) and was instrumental in driving growth in the investment banking business. Prior to PINC, he was Director of Investment Banking and Global Market Solutions Group at Credit Suisse, Director at Deutsche Bank Global Markets and worked with the IL&FS Group as the Head of Origination for the Investment Banking Group, among other leadership roles. He also worked in Citibank NA in the Capital Markets Group.



**Ms. Rajashri Ojha, Non-Executive Independent Director**

Has over 28 years of experience in pharmaceutical industry including in R&D analytical development, technical/CMC documentation QC-QA-QM, regulatory compliance, and registration & marketing approvals globally. She has published many articles and research papers in reputed national and International Journals, she has also been awarded with various leadership awards. She is also an Adjunct Professor at KLE University, Mysore, and an Expert Member of Global Compliance Panel-DE.



**Mr. Krishna Datla, Promoter & Executive Vice Chairman**

A Commerce Graduate from Mumbai University having around 20 years of experience in the industry

A progressive thinker responsible for the decision making process and overseeing new businesses. He has infused a strong sense of global vision thereby opening the opportunities across International markets.



**Mr. Prashant Nagre, Managing Director**

Prashant Nagre is Managing Director of the company. Having spent three decades in the pharmaceuticals industry, he has in-depth experience across spheres encompassing the API business, production, research and Development. Prashant heads strategy and day to day operations including Business Development, budgeting, manufacturing, R&D and allied activities. He holds a Master's in Management Sciences, and also a Post Graduate Diploma in International Trade (IIFT, New Delhi) besides a Degree in Pharmacy.



**Ms. Anupama Datla, Executive Director**

She is a post-graduate in Biotechnology from the Mumbai University and a Science Graduate from the Boston College, USA. Joined FBL in 2006 and went on to join the board in 2007 as the Executive Director. She has taken executive leadership in R&D, quality control, and implementing safety policies and procedures across the organization. She is the author of various patents within the group, is in charge of introducing and implementing new technology platforms into the company and also spearheads the new business development.




**Mr. Satish Varma, Executive Director**

In 1994, he joined the DIL group as the Executive Assistant to the then Managing Director. In this role he garnered extensive operational, management and legal experience across the full scope of the company. In 2003 he joined the Board of Directors of FBL.

In addition to his Executive Board duties, he is also a member of the Stakeholder Relationship Committee.








# Geographical Presence



**Geographical Revenue Mix %  
(FY24) for Vit D3 and Other API**



**International Subsidiaries**  
Delaware, USA: Fermenta Biotech USA LLC  
Nacogdoches, USA: Fermenta USA LLC  
Hamburg, Germany: Fermenta Biotech GmbH



**R&D Centre and Registered Office**



**Manufacturing Facility**



# Manufacturing Plants



## Kullu (Himachal Pradesh)

- Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Acylase as well as CAL B enzymes. A new bulk drug division in 2004 to manufacture various APIs like Vitamin D3, Phenylamidol HCl and Silicon Powder.
- Inaugurated customized premix manufacturing plant in September 2023 and production started in second half of FY24.
- This plant is certified by WHO-GMP, CDSCO-WC, USFDA, CEP – EDQM, HACCP, ISO-9001, ISO-14001, ISO-45001, BRC, FSSC, FSMA, FAMI-QS, HALAL, KOSHER etc.



## Dahej (Gujarat) – Vitamin D3 and Backward Integration for Cholesterol

- Established a dedicated green field manufacturing facility in 2011 to primarily manufacture Vitamin D3.
- This plant is certified WHO-GMP, CDSCO-WC, USFDA, CEP – EDQM, HACCP, ISO-9001, ISO-14001, ISO-45001, BRC, FSSC, FSMA, FAMI-QS, HALAL, KOSHER, etc.
- In 2019, FBL implemented backward integration for manufacturing cholesterol.
- Cholesterol is the key raw material for manufacturing Vitamin D3 derived from wool grease (a by-product of sheep wool scouring).



## Pennepalli (Andhra Pradesh)

- Commissioned a new facility in 2022 to manufacture Fortified Rice Kernel (FRK) in Pennepalli, Tirupati district.
- With this, Fermenta has entered the rice fortification market and bolstered its emerging portfolio in nutrition.
- The FRK produced will be enriched with iron, vitamin B12, and folic acid, in compliance with the Food Safety and Standards Authority of India (FSSAI) guidelines for rice fortification.





# Accreditations & Certifications\*



\*Accreditations & Certifications are products / site specific



## R&D

- Modern, fully equipped, DSIR approved Research & Development facility complemented by highly skilled and committed scientists.
- Providing integrated solutions, processes and products for Biotech and Active Pharmaceutical Ingredients (API)
- API R&D, combined with expertise on photochemistry, chromatography and multi-step process development skills
- Biotech R&D has got wide experience in the areas of bacterial fermentation, enzyme expression, immobilization platforms and process development in various enzymatic applications
- Dedicated formulation development lab which currently focuses on solutions for various value-added formats in the nutrition basket, including premix (liquids and solids)




## Driven by the Discover, Develop & Deliver Philosophy



## Quality



- Quality Assurance: Responsible for implementing quality systems, regulatory audits (national and international including customer and GMP) and releasing all manufactured products
- Regulatory Affairs: Ensures compliance with national and international regulatory requirements
- Quality Control: Responsible for all analysis, from analytical support to validations




## BUSINESS OVERVIEW



# About Vitamin D3

- Vitamin D3 (Cholecalciferol) is a fat-soluble vitamin, responsible for calcium absorption in the body.
- Vitamin D3 is produced by the body when skin is exposed to UV-B rays from the sun. Vitamin D can also be obtained from dietary sources.
- 80-90% of the Indian population<sup>1</sup>, and over 1 billion people worldwide<sup>2</sup>, suffer from low Vitamin D levels – due to an indoors lifestyle and poor diet.





## For Humans

- Vitamin D has been linked to a multitude of health benefits such as general health and wellbeing, bone and mental health as well as management and prevention of certain lifestyle disorders such as diabetes and cardiovascular disease.
- Vitamin D has also been shown to play an important role in immunity and protection against respiratory infections.<sup>3</sup>
- Recent research has suggested that Vitamin D supplementation may reduce the risk of COVID-19 complications. Citing Vitamin D as a potent immune-modifying micronutrient, studies have advocated supplementation and called on governments to increase recommended levels.<sup>6,7,8</sup>

## For Animals

- Vitamin D has been seen to improve bone strength and density as well as fertility. It has the potential to enhance yield and quality of milk, meat and eggs.<sup>4,5</sup>



## References:


1. J Family Med Prim Care. 2018;7(2):324–330.
2. J Pharmacol Pharmacother. 2012;3(2):118–126.
3. Mayo Clin Proc. 2013;88(7):720–755.
4. J Dairy Sci. 1974 Sep;57(9):985-91.
5. Poult Sci. 1995 Dec;74(12):1919-34.
6. Aliment Pharmacol Ther, 51: 1434-1437., April 2020
7. TILDA, Irish Medical Journal, April 2020
8. Nutrients. 2020;12(4):988., April 2020






- FBL is a leader in manufacturing Vitamin D3, and has the distinction of being the only organization in India to manufacture Vitamin D3
- The company has a Non-China dependent supply chain.

**CAGR Growth FY15 to FY24**



**Vitamin D3 Revenue (INR Mn)**



## Unique

One of three CEP-certified companies worldwide



## Pioneering

Use of proprietary technology to manufacture Vitamin D3 API



## Knowledge Capital

55 years of experience and the proficiency in manufacturing Vitamin D3 with a base of over 350+ customers



## Scale

Among the top three producers of Vitamin D3 API in the world



## One Stop Shop

Manufactures Vitamin D3 for various applications (human and veterinary healthcare, animal feed)



## Integrated

Superior quality and cost effectiveness from backward integrated manufacturing operations





## Standardized

Products and manufacturing facilities certified by various global health regulatory like US-FDA (FFRN), American Vegetarian Association, FAMI-QS, WHO-GMP etc.

# Manufacturing Process and Applications


## Backward Integrated Manufacturing Process



Currently processing to manufacture Vitamin D3 from cholesterol

Completed backward integration to manufacture cholesterol

## Vitamin D3 Applications



## Heritage of innovation in enzymes



## One-stop Destination for Green Chemistry

FBL's core expertise spans from microbial screening, fermentation, immobilization, biocatalysis, enzyme-mediated antibiotic synthesis to API intermediates & APIs

FBL is a pioneer in the development and production of fermentation-based Penicillin G Amidase enzyme (PGA) and commercialized immobilized enzymes in India

The Company is also actively working towards promoting CAL B lipase in niche applications which can revolutionize various critical API processes



## APIs & Other intermediaries

- For over 25 years, FBL is a trusted and reliable source of Phenyramidol HCl (muscle relaxant) & Silicon Powder (anti-flatulent) APIs.



## Environmental Solutions

- FBL's Environmental Solutions provide unique advantages in waste water treatment and management through integrated biotechnology.



## Fish Oil Cholesterol

- As an extension to its product portfolio, FBL has started manufacturing cholesterol from fish oil for applications in the aquaculture market (specifically the shrimp feed segment), which was commercialized in FY21



## Nutritional Ingredients

- FBL sources Natural Astaxanthin for human and animal nutrition applications for the Indian subcontinent.



## Fortified Rice Kernel

- FBL offers Fortified Rice Kernel (FRK) from its newly commissioned manufacturing facility in Andhra Pradesh.



## Vitamins

- FBL offers Vitamin K1 in API USP grade as well as Spray Dried format for applications in pharmaceutical, dietary and nutritional supplements as well as food.
- FBL has commercialized Vitamin E50 for applications in animal nutrition.



## Customized Premixes

- FBL offers customized premixes for human nutrition including staple food fortification as well as food & beverages.
- It has commercialized Vitamin AD2 premix for oil fortification and FRK premix for Fortified Rice Kernel (rice fortification).



# Nutraceutical Product Offerings



## Vitamin D3 and its various formats for

Pharmaceuticals  
Dietary & Nutritional Supplements  
Food  
Feed  
Veterinary Science  
Rodenticide

## Variants of Fat soluble vitamins

Vitamin E  
Vitamin K1

## Nutrition portfolio

Fortified Rice Kernel  
Natural Astaxanthin  
Customized Premixes



Current Portfolio



Multi Vitamin



Nutraceutical

## Products Recently Launched

Vitamin E50

Vitamin K1

Fortified Rice  
Kernel

Customized  
premix

Q2  
FY23

Q1  
FY24

Q1  
FY24

Q3  
FY24

## New Product Launch Timeline

Vitamin D3  
Spray Dried 100

Plant Based  
Vitamin D3

Q2  
FY25

Q2  
FY25



# Growth Drivers



## Internal Factors

- Strong manufacturing capabilities with enhanced capacity utilizations to meet YoY production targets
- Enhancing control and reduced dependence by backward integration
- Sales footprint in 60+ countries spread across the globe
- Expanding into value added formats of vitamins like A, E, D, manufacturing Vitamin K and further focus on development of novel anti-oxidants, customized premixes etc.
- Setting up plant at Kullu, Himachal Pradesh for customized premixes.

## External Factors

- Increased prescription market for Vitamin D3 formulations
- Growing need for applications in the form of tablets, capsules and syrups
- Government guidelines related to use of Vitamin D in food fortification
- Significant portion of global population is Vitamin D deficient or insufficient
- Understanding of Vitamin D benefits has moved beyond bone & joint health to management of lifestyle disorder as well as general health, wellbeing and immunity





## Enhanced Focus

Exiting of non-core business activities and laying long term emphasis on expanding the Nutraceutical business.



## Capital Allocation Plans

All future capital allocation will be focused towards Nutrition business.



## Real Estate Business

The company has taken steps towards monetizing these assets at appropriate valuations.



## Debt

The company has a long term debt of approximate INR 65 Cr with a low average cost of debt at ~ 7% pa. Around Rs 51 Cr of the long term debt towards the real estate was repaid in FY24.



## Dividend Policy

The company strives to have a prudent dividend policy with a healthy balance between shareholders' returns and organizational requirement for future growth.





## INDUSTRY OVERVIEW



# Vitamin D & Nutraceutical Industries & Drivers



## VITAMIN D INDUSTRY

- The Vitamin D market is estimated to account for about USD 1.25 billion in 2021 and is projected to reach a value of nearly USD 1.9 billion by 2027, growing at a CAGR of 7.1% from 2023 to 2027.
- Vitamin D insufficiency affects almost 50% of the population worldwide. An estimated 1 billion people worldwide, across all ethnicities and age groups, have Vitamin D deficiency. In India, the prevalence of Vitamin D deficiency ranged from 40% to 99%, with most of the studies reporting a prevalence of 80%–90%.

*Source: Marketsandmarkets (2022), M Holick; N Engl J Med. 2007 Jul 19;357(3):266-81., J Family Med Prim Care. 2018 Mar-Apr; 7(2): 324–330.*


## NUTRACEUTICAL INDUSTRY

- The global nutraceuticals market was USD 396.29 billion in 2021 and is projected to reach USD 636.60 billion by 2030, growing at a CAGR of 5.2%. The nutraceuticals market in India accounts for almost 2% of overall nutraceuticals sales across the globe. It is anticipated that the market growth will increase rapidly, accounting for 3.5% of overall global market by the end of 2023.
- The nutraceutical ingredients market is estimated to be valued at \$185.2 billion in 2022 and is projected to reach \$261.70 billion by 2027, at a CAGR of 7.2 per cent from 2022 to 2027. Asia Pacific is projected to be the fastest-growing market for the forecast period and India is also projected to be the fastest-growing country in the region.
- Following the COVID-19 pandemic, consumer focus has switched to illness prevention, resulting in an increase in demand for nutraceuticals. A trend toward health maintenance, early intervention, and disease risk reduction are major pillars furthering the nutraceuticals industry.

*Source: Vitafoods Insights (2022), Global Market Insights on Global Nutraceuticals Market*



# Vitamin D3 500 Animal Feed Price Trend



AL GROWTH

unsubstantiated editing  
unsubstantiated editing

22.10

24.78

## FINANCIAL OVERVIEW



# Annual Standalone Financial Performance



PARTICULARS (INR Mn)	FY24	FY23	Y-o-Y
<b>Operational Revenue</b>	<b>3,071</b>	<b>3,289</b>	<b>(6.6)%</b>
Total Expenses	2,701	2,905	(7.0)%
Operational EBITDA	<b>370</b>	<b>384</b>	<b>(3.6)%</b>
<b>Operational EBITDA Margins (%)</b>	<b>12.05%</b>	<b>11.68%</b>	<b>37%</b>
Other Income	82	85	(3.5)%
Depreciation	237	245	(3.3)%
Finance Cost	171	208	(17.8)%
<b>Profit/ (Loss) Before Tax and Exceptional Items</b>	<b>44</b>	<b>16</b>	<b>NA</b>
Exceptional Items	(90)	(596)	(84.9)%
Tax	141	(10)	NA
<b>Profit/(Loss) after Tax</b>	<b>(187)</b>	<b>(570)</b>	<b>(67.2)%</b>
<b>PAT Margins (%)</b>	<b>NA</b>	<b>NA</b>	<b>NA</b>
Other Comprehensive Income	2	1	NA
<b>Total Comprehensive Income</b>	<b>(185)</b>	<b>(574)</b>	<b>(67.8)%</b>
Diluted EPS (INR)	(6.49)	(19.75)	NA

# Historical Standalone Balance Sheet



PARTICULARS (INR Mn)	FY24	FY23	FY22
<b>Equity</b>	<b>3,142</b>	<b>3,360</b>	<b>3,959</b>
a) Equity share capital	144	144	144
b) Other equity	2,998	3,216	3,815
<b>Liabilities</b>			
<b>Non-current liabilities</b>	<b>895</b>	<b>1,152</b>	<b>1,300</b>
a) Financial liabilities			
i) Borrowings	426	835	1,147
ii) Lease liabilities	55	20	37
iii) Other financial liabilities	35	11	7
b) Provisions	54	46	57
d) Other non-current liabilities	325	240	52
<b>Current Liabilities</b>	<b>1,609</b>	<b>2,126</b>	<b>1,867</b>
a) Financial liabilities			
i) Borrowings	897	1,333	1,214
ii) Lease liabilities	10	7	11
ii) Trade payables	530	519	456
iii) Other financial liabilities	76	91	128
b) Provisions	6	6	8
c) Other current liabilities	83	166	47
d) Current tax liabilities (Net)	4	3	3
e) Contract Liability	3	1	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,646</b>	<b>6,638</b>	<b>7,126</b>

PARTICULARS (INR Mn)	FY24	FY23	FY22
<b>Assets</b>			
<b>Non-current Assets</b>	<b>3,264</b>	<b>4,105</b>	<b>3,974</b>
a) Property, plant and equipment	2,364	2,048	1,935
b) Capital work-in-progress	16	419	299
c) Right of use assets	154	117	157
d) Investment property	54	287	668
e) Goodwill	41	41	41
f) Other intangible assets	54	74	66
g) Intangible assets under development	-	31	47
h) Investments			
i) Investments in subsidiaries	32	122	127
i) Financial assets			
i) Investments	4	4	3
ii) Loans	74	72	64
iii) Others financial assets	40	210	67
iv) Trade Receivables	117	180	-
j) Deferred tax assets (Net)	220	333	333
k) Non-current tax assets (Net)	82	103	132
l) Other non-current assets	12	64	35
<b>Current Assets</b>	<b>2,382</b>	<b>2,533</b>	<b>3,152</b>
a) Inventories	786	1,097	1,296
b) Financial assets			
i) Trade receivables	771	674	1,178
ii) Cash and cash equivalents	186	321	102
iii) Bank balances other than (iii) above	380	230	206
iv) Investments	-	28	-
v) Loans	47	10	-
vi) Other financial assets	13	9	50
c) Other current assets	167	132	320
d) Contract assets	32	32	-
<b>TOTAL ASSETS</b>	<b>5,646</b>	<b>6,638</b>	<b>7,126</b>

# Historical Consolidated Income Statement



PARTICULARS (INR Mn)	FY24	FY23	FY22	FY21
<b>Operational Revenue</b>	<b>3,357</b>	<b>3,499</b>	<b>3,985</b>	<b>3,773</b>
Total Expenses	3,082	3,323	3,371	2,956
<b>Operational EBITDA</b>	<b>275</b>	<b>176</b>	<b>614</b>	<b>817</b>
<b><i>Operational EBITDA Margins (%)</i></b>	<b><i>8.19%</i></b>	<b><i>5.12%</i></b>	<b><i>15.41%</i></b>	<b><i>21.65%</i></b>
Other Income	118	86	81	82
Depreciation	247	282	255	203
Finance Cost	170	208	171	180
<b>Profit/(Loss) before Exceptional Items and Tax</b>	<b>(24)</b>	<b>(228)</b>	<b>269</b>	<b>516</b>
Exceptional Items	(74)	(285)	-	-
Tax	140	18	118	91
<b>Profit/(Loss) after Tax</b>	<b>(240)</b>	<b>(531)</b>	<b>154</b>	<b>455</b>
<b><i>PAT Margins (%)</i></b>	<b><i>NA</i></b>	<b><i>NA</i></b>	<b><i>3.86%</i></b>	<b><i>12.06%</i></b>
Other Comprehensive Income	(2)	(15)	7	(2)
<b>Total Comprehensive Income</b>	<b>(242)</b>	<b>(546)</b>	<b>161</b>	<b>423</b>
Diluted EPS (INR)	(7.99)	(17.7)	5.33	15.69

\*Total OCI is calculated Excluding Non-controlling Interest

# Historical Consolidated Balance Sheet



PARTICULARS (INR Mn)	FY24	FY23	FY22
<b>Equity</b>	<b>2,851</b>	<b>3,126</b>	<b>3,714</b>
a) Equity share capital	144	144	144
b) Other equity	2,744	3,009	3,577
c) Non-controlling interests	(37)	(27)	(7)
<b>Liabilities</b>			
<b>Non-current liabilities</b>	<b>894</b>	<b>1,152</b>	<b>1,283</b>
a) Financial liabilities			
i) Borrowings	425	836	1,147
ii) Lease liabilities	55	20	20
iii) Other financial liabilities	35	11	7
b) Provisions	54	46	56
c) Other non-current liabilities	325	239	52
<b>Current Liabilities</b>	<b>1,733</b>	<b>2,087</b>	<b>2,071</b>
a) Financial liabilities			
i) Borrowings	897	1,333	1,214
ii) Lease liabilities	10	7	11
ii) Trade payables	649	458	646
iii) Other financial liabilities	77	91	128
b) Provisions	11	26	10
c) Other current liabilities	83	168	59
d) Current tax liabilities (Net)	3	3	3
e) Contract Liability	3	1	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>5,478</b>	<b>6,365</b>	<b>7,068</b>


PARTICULARS (INR Mn)	FY24	FY23	FY22
<b>Assets</b>			
<b>Non-current Assets</b>	<b>3,061</b>	<b>3,835</b>	<b>3,928</b>
a) Property, plant and equipment	2,364	2,048	1,935
b) Capital work-in-progress	16	419	299
c) Right of use assets	154	117	139
d) Investment property	54	287	673
e) Goodwill	41	115	109
f) Other intangible assets	72	102	129
g ) Intangible assets under development	-	31	47
h) Financial assets			
i) Investments	4	4	3
ii) Loans	3	2	-
iii) Others financial assets	40	210	67
i) Deferred tax assets (Net)	220	333	360
j) Non-current tax assets (Net)	82	103	132
k) Other non-current assets	11	64	35
<b>Current Assets</b>	<b>2,417</b>	<b>2,530</b>	<b>3,140</b>
a) Inventories	874	1,301	1,595
b) Financial assets			
i) Trade receivables	698	416	871
ii) Cash and cash equivalents	218	353	130
iii) Bank balances other than (iii) above	380	230	206
iv) Investments	-	28	-
v) Loans	47	10	-
vi) Other financial assets	9	4	3
c) Other current assets	160	156	335
d) Contract Assets	31	32	-
<b>TOTAL ASSETS</b>	<b>5,478</b>	<b>6,365</b>	<b>7,068</b>




# Historical Consolidated Financial Performance




### Operational Revenue (INR Mn)




### Operational EBITDA (INR Mn) & Margins (%)




### PAT (INR Mn) & Margins (%)




### RoCE & RoE (%)



### Working Capital Days



### Net Debt to Equity (x)





*No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management Fermenta Biotech Limited ("Company" or "FBL"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.*

*Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.*

*This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.*

*This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.*

**Valorem Advisors Disclaimer:**

*Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.*



**For further information please contact our Investor Relations Representatives:**

**Mr. Anuj Sonpal**

**Valorem Advisors**

Tel: +91-22-4903-9500

Email: [fermenta@valoremadvisors.com](mailto:fermenta@valoremadvisors.com)

Kit Link: <https://www.valoremadvisors.com/fermenta>



Thank You